A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy-Reference-Cited by-同舟云学术

A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy

Published:2020-05-25 Issue:9 Volume:61 Page:2136-2144
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Asklid Anna¹²,Eketorp Sylvan Sandra¹,Mattsson Agnes¹³,Winqvist Maria¹⁴,Johansson Hemming¹,Österborg Anders¹⁴,Hansson Lotta¹⁴

Affiliation:

1. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden;

2. Department of Oncology, Karolinska University Hospital, Stockholm, Sweden;

3. Department of Internal Medicine, Stockholm, Sweden;

4. Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1765233

Reference20 articles.

1. Regionala Cancercentrum i samverkan. Nationellt kvalitetsregister lymfom; Årsrapport från Nationella kvalitetsregistret för lymfom, diagnosperioden 2000-2017. Available from: https://wwwcancercentrumse/samverkan/cancerdiagnoser/blod-lymfom-myelom/lymfom-lymfkortelcancer/kvalitetsregister/

2. Regionalt Cancercentrum i samverkan. Nationellt vårdprogram Aggressiva B-cellslymfom. 2018-02-27 Version: 3.0. Available from: https://wwwcancercentrumse/samverkan/cancerdiagnoser/blod-lymfom-myelom/lymfom-lymfkortelcancer/vardprogram/gallande-vardprogram-aggressiva-b-cellslymfom/

3. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

4. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

5. Diffuse Large B-cell Lymphoma in the Elderly: A Review of Potential Difficulties

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma;Journal of Clinical and Experimental Hematopathology;2023-12-26

2. Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study;The Oncologist;2023-04-13

3. Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [Grupo de Estudio de Linfoproliferativos de Latino América (GELL)];Hematology;2022-11-03

4. Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma;The Oncologist;2021-08-12

5. Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment – A systematic review;Critical Reviews in Oncology/Hematology;2021-04